Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $43.29 million versus the consensus estimate of $41.48 million.

Fiscal Year 2019 revenue was $168.796 million, EPS was $0.69.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.